Intech Investment Management LLC Makes New $650,000 Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Intech Investment Management LLC acquired a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 13,727 shares of the company’s stock, valued at approximately $650,000.

A number of other institutional investors have also modified their holdings of KYMR. Values First Advisors Inc. acquired a new position in Kymera Therapeutics during the third quarter valued at approximately $61,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Kymera Therapeutics by 27.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after acquiring an additional 504 shares during the period. Comerica Bank lifted its holdings in shares of Kymera Therapeutics by 13.7% during the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after acquiring an additional 400 shares in the last quarter. Public Employees Retirement Association of Colorado acquired a new position in shares of Kymera Therapeutics during the 2nd quarter valued at $139,000. Finally, Quest Partners LLC boosted its position in Kymera Therapeutics by 1,402.0% during the 2nd quarter. Quest Partners LLC now owns 5,212 shares of the company’s stock worth $156,000 after purchasing an additional 4,865 shares during the period.

Kymera Therapeutics Stock Performance

Shares of KYMR stock opened at $46.85 on Friday. The stock has a market capitalization of $3.03 billion, a price-to-earnings ratio of -20.02 and a beta of 2.21. Kymera Therapeutics, Inc. has a one year low of $19.73 and a one year high of $53.27. The company’s 50-day simple moving average is $46.82 and its 200-day simple moving average is $42.22.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.01. The company had revenue of $3.74 million during the quarter, compared to analyst estimates of $10.34 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business’s revenue was down 20.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.90) EPS. As a group, research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have commented on the company. Stephens initiated coverage on Kymera Therapeutics in a research report on Monday, November 18th. They issued an “overweight” rating and a $65.00 price objective on the stock. Guggenheim boosted their price target on Kymera Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. Wolfe Research raised shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price objective for the company in a research report on Monday, August 26th. Leerink Partners reissued an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Monday, September 9th. Finally, Leerink Partnrs raised shares of Kymera Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $52.13.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of Kymera Therapeutics stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 15.82% of the stock is owned by insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.